Prescription Drug Monitoring Program (PDMP)

District of Columbia

Information contained in this presentation is accurate as of September 2017
Meet the Speaker

Tadessa Harper-Nichols
Program Specialist – Pharmaceutical Control Division
What is a Prescription Drug Monitoring Program?

PDMPs are electronic databases used to monitor prescription trends within a jurisdiction by reporting the dispensation of targeted controlled drugs.

Information is collected from dispensers to monitor controlled substance dispensations.

Prescriber’s and dispensers are encouraged to use PDMP data to make informed patient care decisions.

This information may be used to monitor matters of substance abuse, fraud or diversion.

PMP AWARxE (developed by Appriss) is the software vendor for the DC PDMP.
## DC PDMP Timeline

<table>
<thead>
<tr>
<th>Events</th>
<th>Dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stakeholder Meeting to review Draft Legislation</td>
<td>February 2012</td>
</tr>
<tr>
<td>Legislation Introduced in City Council</td>
<td>September 2012</td>
</tr>
<tr>
<td>Committee on Health Hearing</td>
<td>July 2013</td>
</tr>
<tr>
<td>Legislation Passed</td>
<td>February 2014</td>
</tr>
<tr>
<td>Draft regulations Ready</td>
<td>Fall 2014</td>
</tr>
<tr>
<td>Stakeholder Meeting on Draft Regulations</td>
<td>November 2014</td>
</tr>
<tr>
<td>Regulation Effective</td>
<td>December 11th 2015</td>
</tr>
<tr>
<td>90 Day Notice Sent</td>
<td>May 15th 2016</td>
</tr>
<tr>
<td>Program Registration</td>
<td>July 1st 2016</td>
</tr>
<tr>
<td>Reporting Begins</td>
<td>August 15th 2016</td>
</tr>
<tr>
<td>Database Access Launched</td>
<td>October 19th 2016</td>
</tr>
<tr>
<td>PDMP Project Transitioned to Program</td>
<td>November 30, 2016</td>
</tr>
</tbody>
</table>
DC PDMP Overview

Covered Substance
- All drug products containing Cyclobenzaprine or Butalbital
- All controlled substances included in schedules II, III, IV and V

Administer
- The direct application of a controlled substance, whether by injection, inhalation, ingestion, or any other means, to the body of a patient or research subject by a practitioner (or in the practitioner’s presence, by the practitioner’s authorized agent) or the patient or research subject at the direction of and in the presence of the practitioner

Dispense
- To distribute a drug to an ultimate user or research subject by or pursuant to the lawful order of a practitioner, including the prescribing, administering, packaging, labeling, or compounding necessary to prepare the substance for that delivery

Reporting Period
- The 24 hour time period immediately following the dispensing of a covered substance

Quality Improvement Organizations
Sharing Knowledge. Improving Health Care.
CENTERS FOR MEDICARE & MEDICAID SERVICES
# Data Exchange Time Period

## Prescriber Information
- Prescriber’s DEA number, NPI number or other mutually acceptable identification number
- Full name
- Date prescription was issued

## Dispenser Information
- Dispenser’s DEA number, NPI number or other mutually acceptable identification number
- Facility
- Address
- Telephone number
- Date prescription was dispensed

## Medication Processing Information
- Prescription number
- Prescription type (new or refill)
- Number of refill being dispensed (if applicable)
- NDC code of the drug dispensed
- Quantity dispensed
- Day’s supply dispensed
- Number of refills ordered

## Patient Information
- Full name
- Address
- Telephone number
- Date of Birth
- Gender
- Payment Method
Exceptions/Exclusions for Reporting

• A DC licensed methadone treatment program or substance abuse treatment pharmacy or facility

• A DC licensed pharmacy that dispenses controlled substances (schedules II-V, cyclobenzaprine; and butalbital) for inpatient hospital are or nursing home patients only

• A pharmacy or facility that dispensing covered substances to inpatients in hospices

• A pharmacy or a facility that never possesses or dispenses controlled substance (schedules II-V), or cyclobenzaprine and butalbital

• A dispensing facility that is experiencing a hardship created by a natural disaster or other emergency beyond the control of the licensee

• An ongoing controlled research project or clinical trial approved by a regionally accredited institution of higher education or under the supervision of a governmental agency
DC PDMP DATA SUBMITTER WAIVER FORM

I request an exemption from reporting to the District of Columbia Prescription Drug Monitoring Program (DC PDMP).

I certify that: (CHECK ONE ONLY)

☐ I represent a DC licensed methadone treatment program or substance abuse treatment pharmacy or facility and therefore am exempt from reporting data, as defined in District of Columbia regulation 10301.5(b).

☐ I represent a DC licensed hospital pharmacy that distributes controlled substances (schedules II-V, cyclobenzaprine, and butalbital), as defined in District of Columbia regulation 10301.5(c), for inpatient hospital care only.

☐ I represent a pharmacy or facility that dispenses covered substances to inpatients in hospices licensed or certified by the Department, as defined in District of Columbia regulation 10301.5(d).

☐ I represent a pharmacy or a facility that never possesses or dispenses controlled substance (schedules II-V, cyclobenzaprine and butalbital), as defined in District of Columbia regulation 10302.1(a)(6) prescriptions and request a permanent zero report, as defined in District of Columbia regulation 10304.

☐ I represent a dispensing facility that is experiencing a hardship created by a natural disaster or other emergency beyond the control of the licensee, as defined in District of Columbia regulation 10305.2(a). Please provide description in a separate document:

☐ I represent an ongoing controlled research project or clinical trial approved by a nationally accredited institution of higher education or under the supervision of a governmental agency, as defined in District of Columbia regulation 10305.2(b). Please attach a description of the research project.

Comments:

(Please limit to 60 characters, including spaces)

I further certify that if this pharmacy or facility begins to dispense controlled substance (schedules II-V, cyclobenzaprine, or butalbital prescriptions that qualify for reporting under the provisions of District of Columbia regulation 10302.1(a)(6)), I will immediately notify the DC PDMP and will commence reporting immediately.

Requests and questions should be submitted to the DC PDMP via email or fax. Upon receipt of a complete Waiver, the Program may take up to thirty (30) business days to process and respond.

E-mail: doh.pdmp@dcmhs.gov; Fax: 877-362-4252

The Program may grant exceptions and waivers on a case-by-case basis, which shall be subject to the terms and conditions stated in this waiver, limited to a specified time period, and subject to being vacated. Licensees must reapply to renew waivers Denial by the Program of a request for a waiver shall be deemed a final Department action. A dispensing pharmacy request for a waiver is denied when it seek review of the final Department action in the Superior Court of the District of Columbia within twenty (20) days after receipt of the notice. The review shall be on the record review of the decision, and not a de novo review.

For Government Use Only

Date Received (mm/dd/yy)

Approved

Denied

Term (mm/dd/yy)

Expiration Date (mm/dd/yy)

Director or Designee Signature

Date of action (mm/dd/yy)

Reason for denial:

(Please limit to 60 characters, including spaces)
Zero Reports

- Zero report forms must be completed when covered substances are not dispensed during the reporting period.
- Due 24 hours after last report.
- Permanent zero status may be requested if covered substances will not be dispensed for a prolonged period of time.
- Permanent zero reports are null upon dispensation of a covered substance.
PDMP Users

Prescribers
Dispensers
Delegates
Authorized Agents

Patients
Policymakers
Researchers
Registration

Prescription Drug Monitoring Program

The Prescription Drug Monitoring Program (PDMP) aims to improve the District’s ability to identify and reduce diversion of prescription drugs in an efficient and cost effective manner that will not impede the appropriate medical utilization of controlled substances; and to enhance patient care by providing prescription monitoring information that will assure legitimate use of controlled substances in health care, including palliative care, research and other medical and pharmacological uses.

PDMP Database Access

- Prescription Drug Monitoring Program Law
- Prescription Drug Monitoring Program Final Rulemaking
- Notices
- Guides
- Forms

https://doh.dc.gov/PDMP
Registration
Welcome to DC PDMP.

You have successfully signed up for DC PDMP. Your email is linked.registrant@email.com. Please follow the link to verify your email.

Additional registration instructions:

Role: Pharmacist
## Approved Users

<table>
<thead>
<tr>
<th>User Role</th>
<th># of Accounts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician (MD, DO)</td>
<td>518</td>
</tr>
<tr>
<td>Pharmacist</td>
<td>284</td>
</tr>
<tr>
<td>Nurse Practitioner / Clinical Nurse Specialist</td>
<td>131</td>
</tr>
<tr>
<td>Pharmacist in Charge</td>
<td>80</td>
</tr>
<tr>
<td>Physician Assistant</td>
<td>75</td>
</tr>
<tr>
<td>Dentist</td>
<td>30</td>
</tr>
<tr>
<td>VA Prescriber</td>
<td>13</td>
</tr>
<tr>
<td>Null</td>
<td>8</td>
</tr>
<tr>
<td>Podiatrist (DPM)</td>
<td>8</td>
</tr>
<tr>
<td>Pharmacy Technician</td>
<td>6</td>
</tr>
<tr>
<td>Admin</td>
<td>4</td>
</tr>
<tr>
<td>Midwife with Prescriptive Authority</td>
<td>3</td>
</tr>
</tbody>
</table>

Last updated on 9/24/2017
Dispenser Role

• Dispensers are required to report all covered substances dispensed unless exempt

• May access database to analyze patient history of covered substance

• If a correction to the information is needed it must be corrected by the dispenser within 72 hours

• Must give notice at their facility stating that patient information will be sent to the PDMP

• Dispenser can discuss concerns with the prescriber and patient
Prescriber Role

- Support avoidance of prescribing duplicate or inappropriate therapies that enable diversion

- Detection of patients at risk of drug abuse

- Prescriber’s have access to self-reports illustrating their prescribing activity

- Must provide notice at their practice stating the use of the PDMP

- Any covered substance being dispensed including one’s dispensed at their practice must be reported
Mandates

- A prescriber or dispenser is not required or obligated to access or use the prescription monitoring data.

- Each dispenser of a covered substance must submit the prescription monitoring data required to the Program within twenty-four (24) hours after a covered substance is dispensed for each covered substance dispensed.
## Limitations of Matching Data

### Patient Search

<table>
<thead>
<tr>
<th>Patient Info</th>
<th>Patient Location</th>
<th>PMP Interconnect Search</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name*</td>
<td>Street Address</td>
<td>Connecticut</td>
</tr>
<tr>
<td>Partial spelling</td>
<td></td>
<td>Maryland Requests</td>
</tr>
<tr>
<td>Last Name*</td>
<td>City</td>
<td>Massachusetts</td>
</tr>
<tr>
<td>Partial spelling</td>
<td></td>
<td>Minnesota</td>
</tr>
<tr>
<td>DOB*</td>
<td>State/Province</td>
<td>New York</td>
</tr>
<tr>
<td>MM/DD/YYYY</td>
<td>State Select</td>
<td>Pennsylvania</td>
</tr>
<tr>
<td>Phone Number</td>
<td>Zip Code</td>
<td>Rhode Island</td>
</tr>
<tr>
<td></td>
<td></td>
<td>South Carolina</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Virginia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>West Virginia</td>
</tr>
</tbody>
</table>

### Prescription Fill Dates

- From*  
  No earlier than 3 years from today  
  06/08/2016  

- To*  
  09/06/2017
Data Availability

- PDMP data is accessed through the PMP AWARxE portal by users who have been approved by a PDMP administrator
- Threshold alerts

Set Shopper Alert Thresholds

Trigger a PMP Patient Report Alert when:

- Count of Prescribers: $\geq 4$
- AND
- Count of Pharmacies: $\geq 4$

Within a Time Period of:

- 3 Months
- 6 Months
- 12 Months
DC PDMP is currently connected with the following states through PDMP Interconnect:

- Massachusetts
- West Virginia
- Connecticut
- Rhode Island
- New York
- Virginia
- Maryland
- Pennsylvania
- South Carolina
- Minnesota
Analytics

- Self report analytics – My Rx

<table>
<thead>
<tr>
<th>Prescriptions Written</th>
<th>DEA Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>from</strong></td>
<td>DC555555555</td>
</tr>
<tr>
<td>No earlier than 3 years from today</td>
<td></td>
</tr>
<tr>
<td><strong>to</strong></td>
<td></td>
</tr>
</tbody>
</table>

MM/DD/YYYY

MM/DD/YYYY
Trends and Use Patterns

Tableau Reports

- User Registrations
- Top Prescribers
- Top Dispensers
- Dispensations by Month/Year
- Top Drugs Prescribed by Generic Name/Brand Name
DC PDMP Moving Forward

Opportunities

- Prescriber Report Cards
- Enhanced Analytics Package
- Future Mandates – Prescriber/ Dispenser Use
  - Registration/Review
• Shauna White, PharmD, RPh, MS

• Kofi Onumah, PharmD, RPh
Thank You For Watching!

- For more information on the DC PDMP visit the District of Columbia Department of Health website at (doh.dc.gov/pdmp)

- Questions about the program may be emailed to doh.pdmp@dc.gov

- Free educational programs on opioid prescribing at DC Center for Rational Prescribing (doh.dc.gov/dcrx)